Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance

SIMPLE SUMMARY: PARP inhibitors (PARPi; olaparib) are presently in clinical trials for advanced prostate cancer (PC). Resistance mechanisms are not fully understood in PC compared to ovarian and breast cancers. Our study aimed to identify new molecular mechanisms that affect acquired olaparib-resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Cahuzac, Maxime, Péant, Benjamin, Mes-Masson, Anne-Marie, Saad, Fred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405809/
https://www.ncbi.nlm.nih.gov/pubmed/36010871
http://dx.doi.org/10.3390/cancers14163877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405809/
https://www.ncbi.nlm.nih.gov/pubmed/36010871
http://dx.doi.org/10.3390/cancers14163877

Ejemplares similares